vasomotor symptom – Talk Bio

Actionable Insights Powered by AI

Bayer Receives FDA Approval for Lynkuet, a Novel Non-Hormonal Drug for Menopausal Hot Flashes

2 months ago talkbio0Tagged Approved, Bayer, Elinzanetant, Hot flushes, Lynkuet, Menopause, NK1/NK3 receptors, Non-Hormonal, United States Food and Drug Administration, vasomotor symptom

Bayer; FDA approval; Lynkuet; elinzanetant; hot flashes; menopause; non-hormonal; NK1/NK3 receptors; vasomotor symptoms

Bayer’s Lynkuet (elinzanetant) Wins First-in-World Approval in UK, Challenging Astellas’ Hot Flash Drug

5 months ago talkbio0Tagged Approved, Astellas, Bayer, Elinzanetant, Hot flushes, Lynkuet, Menopause, MHRA, non-hormonal therapy, UK, vasomotor symptom

Bayer; elinzanetant; Lynkuet; menopause; hot flashes; vasomotor symptoms; Astellas; non-hormonal therapy; MHRA approval; UK first approval

Bayer’s Menopause Drug Elinzanetant Achieves Successful Long-Term Results in Phase III Trial, Rivalling Astellas’ Veozah

2 years ago talkbio0Tagged Astellas, Bayer, competition, Elinzanetant, Hot flushes, Long-term, Menopause, Phase 3 Clinical Trials, vasomotor symptom, Veozah

Bayer, Elinzanetant, Menopause drug, Phase III trial, Long-term results, Hot flashes, Vasomotor symptoms, Astellas, Veozah, Competition